Roche PD-L1 immunotherapy Tecentriq non-small cell lung cancer phase III clinical success
September 5, 2016 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Swiss pharmaceutical giant Roche recently announced positive data on the phase III OAK study of PD-L1 tumor immunotherapy Tecentriq (atezolizumab). The study was conducted in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received either platinum-containing chemotherapy or after treatment. Data showed that Tecentriq made total compared with docetaxel chemotherapy. Survival (OS) achieved a statistically significant and clinically significant improvement that met the common primary endpoint of the study. The adverse events observed in this study were consistent with those in the previous Tecentriq study. Roche plans to publish complete data on the study at the upcoming medical conference in 2016.
Previously, the FDA has awarded Tecentriq a breakthrough drug qualification (BTD) for the treatment of PD-L1 (programmed death ligand 1)-positive non-small cell lung cancer (NSCLC), as well as a priority review of Tecentriq for the treatment of NSCLC biologics license applications (BLA). Eligibility and a final review decision will be made on October 19, 2016.
Currently, Roche is conducting eight phase III clinical trials to evaluate Tecentriq monotherapy or in combination with other drugs for the treatment of early and late stage lung cancer.
Atezolizumab is an experimental, fully humanized monoclonal antibody designed to target PD-L1 proteins expressed on the surface of tumor cells and tumor infiltrating immune cells, preventing their binding to PD-1 and B7.1 receptors on the surface of T cells. . By inhibiting PD-L1, atezolizumab is able to activate T cells.
In May of this year, the FDA accelerated the approval of Tecentriq for the treatment of the most common type of bladder cancer, urothelial bladder cancer, which became the first anti-PD-L1 inhibitor approved by the FDA. Meanwhile, urothelial bladder cancer It is also the first approval of Tecentriq for regulatory gains.
Currently, Roche is actively promoting a large clinical development project to investigate the potential of atezolizumab for the treatment of specific types of lung, kidney, breast and bladder cancer. At the same time, Roche is also working to advance the combination therapy of atezolizumab with other drugs to exploit the maximum clinical potential of the drug.
Organic lion`s mane mushroom extract powder is an effective active ingredient extracted from high-quality hericium erinaceus fruiting bodies. The main ingredients of the lion`s mane mushroom are polysaccharides and hericin. The Hericium Erinaceus polysaccharide extracted by hot water has an obvious inhibitory effect on mouse sarcoma 180 and Ehrlich ascites carcinoma and has the functions of digestion and viscera, and it can treat various gastrointestinal diseases such as chronic gastritis and duodenal ulcer All have a good curative effect, which can improve human immunity.
Lion'S Mane Extract,Organic Lion'S Mane Powder,Mushroom Extract Powder,Mane Mushroom Powder
Organicway (xi'an) Food Ingredients Inc. , https://www.organicwayinc.com